Modern Treasury vs Trovata for Life Sciences Consulting Firms

Before evaluating either platform in any depth, list every single active engagement and note whether it's a standard commercial consulting arrangement, cash you can use freely once earned, or a grant-funded or cost-reimbursement project where spending has to track against an approved budget category. Neither Modern Treasury nor Trovata distinguishes restricted from unrestricted cash automatically; that classification has to come from you, tracked either in your accounting system or as manual tagging layered on top of whichever treasury platform you choose.

Federal grants, SBIR awards, and cost-reimbursement contracts with biotech clients each have their own reimbursement cycle, and it's rarely as fast as standard commercial invoicing. A federal grant drawdown can take weeks to process even when your documentation is complete. Understanding each funding source's typical timing, not just an average across all of them, is what lets you tell the difference between a normal reimbursement lag and an actual problem with a specific submission.

Firms working on federal awards often operate under a negotiated indirect cost rate, and demonstrating compliance with that rate is a specific accounting requirement most general treasury platforms were never built for. If indirect cost compliance is a meaningful part of your business, that tracking almost certainly needs to live in a proper project accounting system, not in Modern Treasury or Trovata, both of which show cash movement rather than cost allocation against a negotiated rate.

A boutique life sciences consultancy rarely has spare engineering capacity to build custom ledger logic, which points most firms this size toward Trovata's finance-configurable dashboard for straightforward cash visibility. A larger firm with a mix of commercial and federal work, and genuine platform engineering resources, might consider Modern Treasury's API to tie specific project cash flows to specific funding sources, but that's a build most consultancies in this space don't have the team to maintain well.

Say a firm is waiting on a federal grant drawdown that's running six weeks behind a typical commercial invoice's payment timeline, while payroll for the scientists staffed on that project runs on the usual biweekly clock regardless. This is the moment cash visibility earns its keep, surfacing the gap between committed payroll and reimbursement received early enough that the firm can plan around it rather than discovering the shortfall when it's already tight.

Whichever platform you choose, treat it as a cash visibility tool sitting alongside, not replacing, whatever system tracks restricted funds and indirect cost compliance for your federal and grant-funded work. Mixing those responsibilities is where firms in this space tend to run into trouble, not because either platform does anything wrong, but because neither one was built for the specific compliance tracking that federal funding requires.

Work through the decision in this order:

1. List every engagement and mark whether it is commercial work, usable freely once earned, or grant-funded or cost-reimbursement work tracked against an approved budget.
2. Map reimbursement timing by funding source, since a federal grant drawdown can take weeks even when documentation is complete.
3. Decide whether indirect cost rate tracking is required, and keep it in a system built for that compliance need.
4. Match the platform to engineering capacity: a finance-configurable dashboard for boutiques, an API for firms with platform engineers.
5. Use the treasury platform alongside, not instead of, whatever tracks restricted funds for your grant-funded work.

Picture a fifteen-person consultancy running one commercial biotech engagement, one active SBIR award, and one cost-reimbursement contract with a larger pharmaceutical client, all staffed by overlapping scientists whose payroll runs on the same biweekly schedule regardless of which project they're billing time against. The commercial engagement pays fastest, the cost-reimbursement contract is moderate, and the SBIR drawdown is typically slowest. Without a clear view of cash by funding source, it's easy to assume the firm is comfortably covered because the commercial engagement's fast payment is currently masking a slower reimbursement building up behind it on the other two projects.

Grant-funded and cost-reimbursement work often has a defined end date, and firms sometimes don't have a signed follow-on award lined up before the current one closes out. Watching cash by funding source becomes especially important in the months leading up to that kind of funding cliff, since it's the clearest early signal of how much runway the commercial side of the business alone needs to cover before any new federal award or grant funding, if one is even secured, actually starts flowing again into the firm's accounts.